Trial Profile

a Single-Center, Randomized, Double-Blind, Does-Escalation Phase I Clinical Study to Evaluate the Tolerability, Safety, PK Characteristics of Recombinant Humanized CTLA-4-FC Fusion Protein Injection in Healthy Subjects.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Recombinant Humanized CTLA-4-FC Fusion Protein-Beijing Weidejie Biotechnology (Primary)
Indications Unspecified
Focus Adverse reactions
Sponsors Beijing Weidejie Biotechnology

05 May 2024 Planned End Date changed from 30 Dec 2023 to 31 Dec 2025.
05 May 2024 Planned primary completion date changed from 30 Sep 2022 to 31 Dec 2025.
21 Jul 2023 Planned End Date changed from 30 Nov 2022 to 30 Dec 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com